T. Rowe Price Associates
ARQT icon

T. Rowe Price Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

T. Rowe Price Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.14M Sell
157,778
-290,429
-65% -$6.77M ﹤0.01% 1656
2026
Q1 		$10.6M Sell
448,207
-718,141
-62% -$18.3M ﹤0.01% 1205
2025
Q4 		$33.9M Buy
1,166,348
+1,078,546
+1,228% +$27.6M ﹤0.01% 930
2025
Q3 		$1.66M Buy
87,802
+3,755
+4% +$59.2K ﹤0.01% 1819
2025
Q2 		$1.18M Buy
84,047
+6,107
+8% +$85.6K ﹤0.01% 1908
2025
Q1 		$1.22M Buy
77,940
+35,591
+84% +$501K ﹤0.01% 1854
2024
Q4 		$590K Sell
42,349
-17,799
-30% -$195K ﹤0.01% 2218
2024
Q3 		$560K Buy
60,148
+1,246
+2% +$12.3K ﹤0.01% 2203
2024
Q2 		$548K Buy
58,902
+11,149
+23% +$101K ﹤0.01% 2156
2024
Q1 		$474K Buy
47,753
+1,681
+4% +$12.5K ﹤0.01% 2232
2023
Q4 		$149K Buy
46,072
+23,125
+101% +$62.9K ﹤0.01% 2630
2023
Q3 		$122K Buy
22,947
+622
+3% +$5.29K ﹤0.01% 2625
2023
Q2 		$213K Buy
22,325
+2,560
+13% +$28.4K ﹤0.01% 2505
2023
Q1 		$218K Buy
19,765
+519
+3% +$7.51K ﹤0.01% 2485
2022
Q4 		$285K Sell
19,246
-160,048
-89% -$2.8M ﹤0.01% 2389
2022
Q3 		$3.43M Sell
179,294
-273,763
-60% -$6.2M ﹤0.01% 1277
2022
Q2 		$9.65M Buy
453,057
+4,355
+1% +$89.3K ﹤0.01% 1323
2022
Q1 		$8.64M Sell
448,702
-374,466
-45% -$6.33M ﹤0.01% 1387
2021
Q4 		$17.1M Buy
823,168
+9,474
+1% +$189K ﹤0.01% 1320
2021
Q3 		$19.4M Sell
813,694
-111,264
-12% -$2.54M ﹤0.01% 1304
2021
Q2 		$25.2M Buy
924,958
+268,537
+41% +$7.56M ﹤0.01% 1241
2021
Q1 		$19M Buy
656,421
+393,640
+150% +$12.3M ﹤0.01% 1286
2020
Q4 		$7.39M Sell
262,781
-728,240
-73% -$17.8M ﹤0.01% 1390
2020
Q3 		$29M Sell
991,021
-75,519
-7% -$2.02M ﹤0.01% 1044
2020
Q2 		$32.3M Buy
1,066,540
+85,926
+9% +$2.48M ﹤0.01% 992
2020
Q1 		$29.2M Buy
+980,614
New +$26.3M ﹤0.01% 951

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates's ARQT Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Arcutis Biotherapeutics (ARQT) stake by 65% in Q2 2026, selling an estimated $6.77M and leaving 157,778 shares worth $4.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1656.

T. Rowe Price Associates first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $33.9M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • T. Rowe Price Associates held 157,778 shares of Arcutis Biotherapeutics worth $4.14M as of Q2 2026.
  • T. Rowe Price Associates sold 290,429 Arcutis Biotherapeutics shares in Q2 2026, an estimated $6.77M.
  • Arcutis Biotherapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1656 holding.
  • T. Rowe Price Associates first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • T. Rowe Price Associates's Arcutis Biotherapeutics position peaked at $33.9M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.